Wagner Anjuli, Slyker Jennifer, Langat Agnes, Inwani Irene, Adhiambo Judith, Benki-Nugent Sarah, Tapia Ken, Njuguna Irene, Wamalwa Dalton, John-Stewart Grace
Department of Epidemiology, University of Washington, Box 359300, Seattle, WA, 98104, USA.
Department of Global Health, University of Washington, Box 359931, Seattle, WA, 98104, USA.
BMC Pediatr. 2015 Feb 15;15:10. doi: 10.1186/s12887-015-0325-8.
Despite expanded programs for prevention of mother-to-child HIV transmission (PMTCT), HIV-infected infants may not be diagnosed until they are ill. Comparing HIV prevalence and outcomes in infants diagnosed in PMTCT programs to those in hospital settings may improve pediatric HIV diagnosis strategies.
HIV-exposed infants <12 months old were recruited from 9 PMTCT sites in public maternal child health (MCH) clinics or from an inpatient setting in Nairobi, Kenya and tested for HIV using HIV DNA assays. A subset of HIV-infected infants <4.5 months of age was enrolled in a research study and followed for 2 years. HIV prevalence, number needed to test, infant age at testing, and turnaround time for tests were compared between PMTCT programs and hospital sites. Among the enrolled cohort, baseline characteristics, survival, and timing of antiretroviral therapy (ART) initiation were compared between infants diagnosed in PMTCT programs versus hospital.
Among 1,923 HIV-exposed infants, HIV prevalence was higher among infants tested in hospital than PMTCT early infant diagnosis (EID) sites (41% vs. 11%, p < 0.001); the number of HIV-exposed infants needed to test to diagnose one infection was 2.4 in the hospital vs. 9.1 in PMTCT. Receipt of HIV test results was faster among hospitalized infants (7 vs. 25 days, p < 0.001). Infants diagnosed in hospital were older at the time of testing than PMTCT diagnosed infants (5.0 vs. 1.6 months, respectively, p < 0.001). In the subset of 99 HIV-infected infants <4.5 months old followed longitudinally, hospital-diagnosed infants did not differ from PMTCT-diagnosed infants in time to ART initiation; however, hospital-diagnosed infants were >3 times as likely to die (HR = 3.1, 95% CI = 1.3-7.6).
Among HIV-exposed infants, hospital-based testing was more likely to detect an HIV-infected infant than PMTCT testing. Because young symptomatic infants diagnosed with HIV during hospitalization have very high mortality, every effort should be made to diagnose HIV infections before symptom onset. Systems to expedite turnaround time at PMTCT EID sites and to routinize inpatient pediatric HIV testing are necessary to improve pediatric HIV outcomes.
尽管预防母婴传播艾滋病(PMTCT)项目有所扩大,但感染艾滋病毒的婴儿可能直到患病才被诊断出来。比较在PMTCT项目中诊断出的婴儿与在医院环境中诊断出的婴儿的艾滋病毒感染率和治疗结果,可能会改善儿科艾滋病毒诊断策略。
从肯尼亚内罗毕的9个公共母婴健康(MCH)诊所的PMTCT站点或住院环境中招募12个月以下暴露于艾滋病毒的婴儿,并使用艾滋病毒DNA检测法进行艾滋病毒检测。对一部分4.5个月以下感染艾滋病毒的婴儿进行了一项研究,并随访2年。比较了PMTCT项目和医院站点之间的艾滋病毒感染率、检测所需数量、检测时的婴儿年龄以及检测周转时间。在入组队列中,比较了在PMTCT项目中诊断出的婴儿与在医院诊断出的婴儿的基线特征、生存率和抗逆转录病毒治疗(ART)开始时间。
在1923名暴露于艾滋病毒的婴儿中,在医院检测的婴儿的艾滋病毒感染率高于PMTCT早期婴儿诊断(EID)站点(41%对11%,p<0.001);在医院诊断出一例感染所需检测的暴露于艾滋病毒的婴儿数量为2.4例,而在PMTCT中为9.1例。住院婴儿获得艾滋病毒检测结果的速度更快(7天对25天,p<0.001)。在医院诊断出的婴儿检测时的年龄比在PMTCT中诊断出的婴儿大(分别为5.0个月对1.6个月,p<0.001)。在纵向随访的99名4.5个月以下感染艾滋病毒的婴儿子集中,在开始ART的时间方面,医院诊断出的婴儿与PMTCT诊断出的婴儿没有差异;然而,医院诊断出的婴儿死亡可能性是PMTCT诊断出的婴儿的3倍多(风险比=3.1,95%置信区间=1.3-7.6)。
在暴露于艾滋病毒的婴儿中,基于医院的检测比PMTCT检测更有可能检测出感染艾滋病毒的婴儿。由于住院期间被诊断出感染艾滋病毒的有症状幼儿死亡率非常高,应尽一切努力在症状出现前诊断出艾滋病毒感染。有必要建立系统来加快PMTCT EID站点的周转时间并使住院儿科艾滋病毒检测常规化,以改善儿科艾滋病毒治疗结果。